A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...

Compared with adults aged 65 and older, those aged 18 to 64 are more affected by long COVID neurologic symptoms.

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

The drug has been in the news recently because of incidents of dysgeusia — a bad, metallic taste in the mouth. In clinical trials, 5.6 percent of patients who received Paxlovid experienced ...

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

Your patient presents with pain, swelling and impaired knee function. One rare diagnosis is non-malignant tenosynovial giant ...

There are a wide variety of neurological diseases affecting the brain and nervous system. Understanding the specifics can help you navigate diagnostic tests and choose the best course of treatment.